Carcinoid Tumor Market Report 2026

The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $1.96 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to improved awareness of rare cancers, expansion of oncology care facilities, availability of somatostatin analog therapies, growth of cancer specialty clinics, advancements in neuroendocrine tumor research.

The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing development of novel targeted therapies, rising investments in rare cancer treatment research, expansion of precision oncology approaches, growing adoption of personalized treatment plans, increasing focus on quality-of-life outcomes. Major trends in the forecast period include increasing adoption of targeted neuroendocrine tumor therapies, rising use of combination drug regimens, growing focus on early tumor diagnosis, expansion of specialized oncology treatment centers, enhanced emphasis on long-term disease management.

The increasing obese population is expected to drive the growth of the carcinoid tumor market in the coming years. The obese population includes individuals with a body mass index (BMI) of 30 or higher, indicating an excessive amount of body fat. This rise in obesity is linked to factors such as poor dietary choices, lack of physical activity, sedentary lifestyles, and higher consumption of processed and high-calorie foods. Obesity contributes to the development of carcinoid tumors by promoting chronic inflammation, insulin resistance, and elevated secretion of growth factors that facilitate tumor growth. For example, in May 2025, according to the Office for Health Improvement and Disparities (OHID), a UK government agency, approximately 64.5% of adults (18+) in England were estimated to be either overweight or living with obesity during 2023-2024, slightly up from 64% in the previous period (2022-2023). As a result, the rising obese population is fueling the growth of the carcinoid tumor market.

Major companies operating in the carcinoid tumor market are concentrating on advancements in diagnostic technologies, such as the fully automated chromogranin A test, to improve early detection and treatment outcomes. The automated chromogranin A (CgA) test is a fully automated diagnostic tool used to measure levels of chromogranin A, a biomarker commonly linked to neuroendocrine tumors, including carcinoid tumors. For example, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, received FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This represents the first FDA-approved Chromogranin A (CgA) test and the only automated immunoassay worldwide for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. The assay, designed to measure CgA concentration in human serum, allows laboratories and cancer centers to monitor tumor growth and evaluate treatment effectiveness. By replacing manual laboratory-developed tests, it improves lab efficiency and ensures more accurate result interpretation. The test runs on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, using TRACE technology to deliver precise results in under 30 minutes.

In March 2024, Merck, a US-based multinational pharmaceutical company, acquired Harpoon Therapeutics, Inc., for an undisclosed amount. Through this acquisition, Merck intends to strengthen its oncology pipeline, accelerate the development of innovative immuno-oncology therapies, broaden its therapeutic portfolio, and enhance its capabilities in targeted cancer treatments. Harpoon Therapeutics, Inc., is a US-based biopharmaceutical company focused on developing next-generation T-cell engagers for the treatment of solid tumors.

Major companies operating in the carcinoid tumor market are Novartis AG, Ipsen SA, Pfizer Inc, Merck & Co Inc, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc, Takeda Pharmaceutical Company, Bayer AG, Exelixis Inc, Lexicon Pharmaceuticals Inc, HUTCHMED, Crinetics Pharmaceuticals, Clovis Oncology, Taiho Pharmaceutical, Eisai Co Ltd, Teva Pharmaceutical Industries.

North America was the largest region in the carcinoid tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carcinoid tumor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the carcinoid tumor market by increasing costs of imported oncology drugs, diagnostic reagents, imaging agents, and specialized pharmaceutical ingredients used in treatment and disease monitoring. Oncology centers in North America and Europe are most affected due to dependence on global drug supply chains, while emerging markets face higher treatment costs and access challenges. These tariffs can increase therapy expenses and slow patient access to advanced treatments. However, they are also encouraging regional drug manufacturing, local clinical research, and development of cost-optimized therapeutic alternatives for rare neuroendocrine tumors.

The carcinoid tumor market research report is one of a series of new reports that provides carcinoid tumor market statistics, including carcinoid tumor industry global market size, regional shares, competitors with a carcinoid tumor market share, detailed carcinoid tumor market segments, market trends and opportunities, and any further data you may need to thrive in the carcinoid tumor industry. This carcinoid tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A carcinoid tumor is an uncommon, slow-growing type of neuroendocrine tumor that usually develops in the gastrointestinal tract or lungs. It arises from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms can differ depending on the tumor's location and whether it secretes hormones, sometimes leading to carcinoid syndrome.

The primary disease types of carcinoid tumors include gastrointestinal neuroendocrine tumors (GI NETs), pancreatic neuroendocrine tumors, lung neuroendocrine tumors, and other types. Gastrointestinal neuroendocrine tumors (GI NETs) are abnormal growths that originate from neuroendocrine cells in the digestive system, with carcinoid tumors being a common, slow-growing subtype. Treatments for these tumors include octreotide, lanreotide, telotristat ethyl, capecitabine (Xeloda), 5-fluorouracil (5-FU), doxorubicin (Adriamycin), etoposide (VP-16), dacarbazine (DTIC), streptozocin, and other therapies, administered orally, parenterally, and through other methods. These treatments are available through both online and offline channels and are utilized by various end-users, including hospitals and clinics, academic institutions, and research organizations.

The carcinoid tumor market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The carcinoid tumor market also includes sales of diagnostic tools, pharmaceuticals, chemotherapy agents, radiopharmaceuticals, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.